Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 May;93(5):574-81.
doi: 10.1111/j.1349-7006.2002.tb01293.x.

Enhanced anti-tumor effect of trastuzumab in combination with cisplatin

Ichiro Naruse  1 , Hisao Fukumoto, Nagahiro Saijo, Kazuto Nishio
Affiliations

Enhanced anti-tumor effect of trastuzumab in combination with cisplatin

Ichiro Naruse et al. Jpn J Cancer Res. 2002 May.

Abstract

The oncogenenic transmembrane tyrosine kinase receptor HER-2/neu is a promising target for treatment of HER-2-overexpressing cancers. The humanized anti-HER-2/neu antibody Trastuzumab is under clinical evaluation in combination with chemotherapy against breast cancer. The combination of Trastuzumab and cisplatin is expected to be active against HER-2 / neu-expressing tumors. We examined the mechanisms of this combination effect against human solid tumor cells in the presence of human peripheral blood mononuclear cells (PBMCs) using an in vitro MTT assay. The growth-inhibitory effects of cisplatin (CDDP) on the tumor cells were not significantly affected by Trastuzumab in the absence of effector cells. CDDP alone at a dose of less than 12.5 mM did not affect the viability of PBMCs, as determined by MTT assay, suggesting that PBMCs could exert antibody-dependent cell-mediated cytotoxicity (ADCC) at this CDDP concentration. The combination of Trastuzumab and CDDP showed higher cytotoxic effects against the tumor cells in the presence of PBMCs. The CDDP concentration required to inhibit tumor cell growth by 50% was reduced to approximately 20% by Trastuzumab in the presence of PBMCs at an effector/target ratio of 10. It may be important to select combined chemotherapeutic agents which do not diminish the ADCC activity of Trastuzumab via PBMCs. Both the expression of HER-2 / neu and the ADCC activity may be important determinants of the therapeutic benefit of the Trastuzumab/CDDP combination.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. ) Coussens , L. , Yang‐Feng , T. L. , Liao , Y. C. , Chen , E. , Gray , A. , McGrath , J. , Seeburg , P. H. , Libermann , T. A. , Schlessinger , J. , Francke , U. , Arthur , L. and Axel , U.Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene . Science , 230 , 1132 – 1139 ( 1985. ). - PubMed
    1. ) Semba , K. , Kamata , N. , Toyoshima , K. and Yamamoto , T.A v‐erbB‐related protooncogene, c‐erbB–2, is distinct from the c‐erbB–1/epidermal growth factor‐receptor gene and is amplified in a human salivary gland adenocarcinoma . Proc. Natl. Acad. Sci. USA , 82 , 6497 – 6501 ( 1985. ). - PMC - PubMed
    1. ) Slamon , D. J. , Godolphin , W. , Jones , L. A. , Holt , J. A. , Wong , S. G. , Keith , D. E. , Levin , W. J. , Stuart , S. G. , Udove , J. , Ullrich , A. and Press , M. F.Studies of the HER–2/neu proto‐oncogene in human breast and ovarian cancer . Science , 244 , 707 – 712 ( 1989. ). - PubMed
    1. ) Slamon , D. J. , Clark , G. M. , Wong , S. G. , Levin , W. J. , Ullrich , A. and McGuire , W. L.Human breast cancer: correlation of relapse and survival with amplification of the HER–2/neu oncogene . Science , 235 , 177 – 182 ( 1987. ). - PubMed
    1. ) Seshadri , R. , Firgaira , F. A. , Horsfall , D. J. , McCaul , K. , Setlur , V. and Kitchen , P.Clinical significance of HER–2/ neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group . J. Clin. Oncol. , 11 , 1936 – 1942 ( 1993. ). - PubMed

MeSH terms

LinkOut - more resources